VANCOUVER, British Columbia--(BUSINESS WIRE)--ProtoKinetix Inc. (OTCBB: PKTX) summarizes the highlights of the scientific accomplishments attained over the last 24 months to develop a commercially viable group of products. The first hurdle was to determine that the AAGPTM molecule was stable and lacked toxicity. Upon these confirmations, PKTX concentrated on human cell preservation at various temperatures. Early studies showed a greater than 300% increase in cell preservation down to -20 oC. Efficacy test results showed a 98% red blood cell preservation after being subjected to -15 oC for 9 hrs as opposed to 100% mortality for cells not treated. Further tests showed a significant reduction of platelet aggregation from 22 oC to 0 oC. Scientists at the University of Rouen expanded the family of AAGPTM molecules and found them to be stable and safe. A third party laboratory found that AAGPTM increased heart cell and heart tissue survivability. AAGP™ was shown to slow the aging process of human skin cells at temperatures ranging from 37o C (core body temperature) down to 0o C. More intense stress to human skin cells using H2O2 and UV-C resulted in successful preservation when treated with AAGPTM. World wide patents and subsequent extensions were then filed.
